ATE396182T1 - Hemmstoffe des ep4-rezeptors - Google Patents
Hemmstoffe des ep4-rezeptorsInfo
- Publication number
- ATE396182T1 ATE396182T1 AT04706221T AT04706221T ATE396182T1 AT E396182 T1 ATE396182 T1 AT E396182T1 AT 04706221 T AT04706221 T AT 04706221T AT 04706221 T AT04706221 T AT 04706221T AT E396182 T1 ATE396182 T1 AT E396182T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- alkyl
- group
- aryl
- formula
- Prior art date
Links
- 108091006082 receptor inhibitors Proteins 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0302094.8A GB0302094D0 (en) | 2003-01-29 | 2003-01-29 | EP4 receptor antagonists |
| US44387203P | 2003-01-31 | 2003-01-31 | |
| US50952103P | 2003-10-09 | 2003-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396182T1 true ATE396182T1 (de) | 2008-06-15 |
Family
ID=32830360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04706221T ATE396182T1 (de) | 2003-01-29 | 2004-01-29 | Hemmstoffe des ep4-rezeptors |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1603893B1 (de) |
| JP (1) | JP5015586B2 (de) |
| KR (1) | KR101094003B1 (de) |
| CN (1) | CN100408570C (de) |
| AT (1) | ATE396182T1 (de) |
| AU (1) | AU2004207675B2 (de) |
| CA (1) | CA2514220C (de) |
| DE (1) | DE602004013938D1 (de) |
| DK (1) | DK1603893T3 (de) |
| ES (1) | ES2308139T3 (de) |
| NO (1) | NO332420B1 (de) |
| PT (1) | PT1603893E (de) |
| WO (1) | WO2004067524A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7355049B2 (en) | 2003-06-24 | 2008-04-08 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
| GB0416730D0 (en) | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| US7524870B2 (en) * | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
| JP5069752B2 (ja) | 2006-12-15 | 2012-11-07 | グラクソ グループ リミテッド | Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体 |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| WO2011003300A1 (zh) | 2009-07-09 | 2011-01-13 | 中国科学技术大学 | 羟甲基糠醛的制备方法 |
| CN101367783A (zh) | 2008-10-10 | 2009-02-18 | 中国科学技术大学 | 5-羟甲基糠醛的制备方法 |
| WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| CA2789665C (en) * | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| EP2593447B1 (de) | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel |
| CN102718734A (zh) * | 2012-05-31 | 2012-10-10 | 中国科学技术大学 | 一种4-羟甲基糠酸和2,4-呋喃二甲酸的制备方法 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| KR20150130404A (ko) * | 2013-03-19 | 2015-11-23 | 에스크엣 인크. | 연골질환 치료에서의 ep4 수용체 길항제의 용도 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| JP7816164B2 (ja) | 2020-11-13 | 2026-02-18 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6462708A (en) * | 1987-09-03 | 1989-03-09 | Mitsubishi Electric Corp | Numerical controller |
| US5428037A (en) * | 1993-04-09 | 1995-06-27 | Syntex Pharmaceuticals, Ltd. | Heterocyclic derivatives in the treatment of Ischaemia and related diseases |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| JP2001062708A (ja) * | 1999-08-24 | 2001-03-13 | Ibiden Co Ltd | ウェハ研磨装置用テーブル |
| AU2426602A (en) * | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
| US6700025B2 (en) * | 2001-01-05 | 2004-03-02 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| JP3555620B2 (ja) * | 2001-03-12 | 2004-08-18 | 小野薬品工業株式会社 | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
-
2004
- 2004-01-29 CN CNB200480007457XA patent/CN100408570C/zh not_active Expired - Fee Related
- 2004-01-29 JP JP2006502209A patent/JP5015586B2/ja not_active Expired - Fee Related
- 2004-01-29 ES ES04706221T patent/ES2308139T3/es not_active Expired - Lifetime
- 2004-01-29 AT AT04706221T patent/ATE396182T1/de active
- 2004-01-29 PT PT04706221T patent/PT1603893E/pt unknown
- 2004-01-29 DE DE602004013938T patent/DE602004013938D1/de not_active Expired - Lifetime
- 2004-01-29 AU AU2004207675A patent/AU2004207675B2/en not_active Ceased
- 2004-01-29 WO PCT/GB2004/000347 patent/WO2004067524A1/en not_active Ceased
- 2004-01-29 CA CA2514220A patent/CA2514220C/en not_active Expired - Fee Related
- 2004-01-29 DK DK04706221T patent/DK1603893T3/da active
- 2004-01-29 KR KR1020057014131A patent/KR101094003B1/ko not_active Expired - Fee Related
- 2004-01-29 EP EP04706221A patent/EP1603893B1/de not_active Expired - Lifetime
-
2005
- 2005-08-25 NO NO20053971A patent/NO332420B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004207675B2 (en) | 2010-05-20 |
| AU2004207675A1 (en) | 2004-08-12 |
| NO332420B1 (no) | 2012-09-17 |
| EP1603893B1 (de) | 2008-05-21 |
| CN100408570C (zh) | 2008-08-06 |
| CA2514220A1 (en) | 2004-08-12 |
| EP1603893A1 (de) | 2005-12-14 |
| CN1761657A (zh) | 2006-04-19 |
| NO20053971D0 (no) | 2005-08-25 |
| WO2004067524A1 (en) | 2004-08-12 |
| KR20050097966A (ko) | 2005-10-10 |
| NO20053971L (no) | 2005-10-31 |
| CA2514220C (en) | 2012-02-28 |
| DE602004013938D1 (de) | 2008-07-03 |
| ES2308139T3 (es) | 2008-12-01 |
| KR101094003B1 (ko) | 2011-12-15 |
| JP5015586B2 (ja) | 2012-08-29 |
| DK1603893T3 (da) | 2008-09-08 |
| JP2006516600A (ja) | 2006-07-06 |
| PT1603893E (pt) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004013938D1 (de) | Hemmstoffe des ep4-rezeptors | |
| NL1018251A1 (nl) | Organometallic monoacylalkylphosphines. | |
| ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| ATE458211T1 (de) | Oximderivate und ihre verwendung als latente saüre | |
| TW200615267A (en) | New bicyclic antibiotics | |
| ATE425983T1 (de) | Siloxy substituierte metallocenkatalysatoren | |
| GB2457416A (en) | Directly photodefinable polymer compositions and methods thereof | |
| EA200300777A1 (ru) | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad | |
| DE69521500D1 (de) | Phosphorsäurediester-derivate | |
| NO20025718L (no) | TNF-a-produksjonsinhibitorer | |
| DE60233516D1 (de) | Verbesserungen betreffend optische aufheller | |
| ATE493397T1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| DE602004026071D1 (de) | Aminopyrone und ihre verwendung als atm inhibitoren | |
| MX2010001344A (es) | Compuesto de acido fenilacetico. | |
| EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
| HRP20090474T1 (hr) | Postupak i intermedijeri za sintezu kaspofungina | |
| DE60327922D1 (de) | Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren | |
| DE60011269D1 (de) | Azaidole mit serotonin rezeptor affinität | |
| EA201070010A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| TR200705187T1 (tr) | 2-Kromen hazırlanması için yeni yöntemler | |
| ATE231179T1 (de) | Sauerstoffenthaltende produkte als dieselbrennstoff | |
| HUP0003942A2 (hu) | Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk | |
| EA200970497A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
| BRPI0416678A (pt) | pirazolpirimidinas | |
| DE60325984D1 (de) | 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1603893 Country of ref document: EP |